The study will include any patient treated with Iluvien at designated sites in European countries where marketing authorization has been granted in order to obtain broader safety and usage information.
Study Type
OBSERVATIONAL
Enrollment
559
Unnamed facility
Atlanta, Georgia, United States
Number of participants with adverse events.
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.